跳至主要内容
临床试验/NCT06629363
NCT06629363尚未招募不适用

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

Centre Hospitalier de PAU0 个研究点目标入组 1,000 人开始时间: 2025年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
1,000
主要终点
Decipher the mechanisms responsible for the transition from severe to malignant hypertension

研究概览

简要总结

The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets

详细描述

Malignant hypertension (MH) is an acute and severe form of hypertension that can lead to rapid target organ damage and potentially be fatal within months if not treated. Despite the severity, MH manifests in various phenotypes, suggesting multiple underlying pathophysiological pathways. The HAMA bank aims to address this by collecting biological samples at two distinct time-points:

For " Pre-existing Patients " in the HAMA cohort: A one-time collection focused on genetic analysis. A full sample (equivalent to sample 1 below) may be collected in option.

For Newly Diagnosed Patients (Incident Patients): Sample 1 "Acute Phase": Collected between Day 0 and Day 7 post-admission to any HAMA recruiting centers. This will be used for initial multi-omics analysis. Sample 2 "Chronic Phase": Collected between the 1st and 6th months during a follow-up visit at the investigating center.

These samples will be cross-referenced with clinical and biological data from the HAMA cohort. The cohort follow-up schedule is: 1, 3, 6, 12 months after MH diagnosis and annually for a total of 5 years.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients included in the HAMA cohort with the following critera :
  • Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy)
  • Severe hypertension associated with acute target organ damage due to high blood pressure

排除标准

  • Refusal to participate to the substudy " HAMA bank "
  • patient on chronic dialysis

结局指标

主要结局

Decipher the mechanisms responsible for the transition from severe to malignant hypertension

时间窗: At inclusion and 6 month

Compare the multiomic signature of patients admitted for malignant hypertension, between MHT acute crisis (admission) and resolution (6 month later). Transcriptomic, proteomic and metabolomic evolution between these 2 time points and focus on genetic background in relevant system, like angiogenic, vasoactif system, complement system and inflammasome will be described.

次要结局

  • Focus on the role of complement system in MHT crisis(At inclusion and 6 month)
  • Understand the determinants of the heterogeneity in target organs damages (TOD) during MHT crisis(At inclusion)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Determinants of Malignant Hypertension Onset and... | 临床试验